WuXi Biologics: Plans to repurchase company shares for up to 400 million US dollars.

WuXi AppTec announced that the company has decided to use the repurchase authorization to buy back shares on the open market for a total price not exceeding 400 million US dollars. According to the repurchase authorization granted by the shareholders at the annual general meeting, the company is allowed to repurchase up to 407 million shares. The company believes that the current trading price of the shares does not reflect their intrinsic value or actual business prospects, and the repurchase plan reflects the company's confidence in its own business development prospects. This repurchase will be strictly carried out in accordance with relevant laws and regulations, and whether or not to carry out any repurchase will depend on market conditions and be decided at the discretion of the board of directors, with no guarantee on the timing, quantity, or price of any repurchase.